Amplyx increases Series B funding to $49.2 mln and hires three
San Diego-based Amplyx Pharmaceuticals, which is developing antifungal agents that treat life-threatening fungal infections, has raised its Series B funding round total to $49.2 million. Joining the investor base is 3x5 Partners. In addition to the funding, the company has named Dr. Michael Hodges as chief medical officer; Dr. Karen Shaw as vice president of biology; and Dr. Elizabeth Gordon as vice president of regulatory affairs.
9 February 2016•3 mins read
